MedTrace Logo

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

NCT07668388 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2026-08-10

No results posted yet for this study

Summary

The study is testing UBT251 in participants with type 2 diabetes. The purpose of this clinical study is to find out if UBT251 is effective and safe for treating participants with type 2 diabetes. Participants will either get UBT251, UBT251 placebo, semaglutide, or semaglutide placebo. Which treatment participants get is decided by chance. UBT251 is the treatment being tested and is not yet available for doctors to prescribe, while semaglutide is a medicine used to treat type 2 diabetes that doctors can already prescribe.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

DRUG

UBT251

UBT251 will be administered subcutaneously once-weekly.

DRUG

UBT251 Placebo

UBT251 placebo will be administered subcutaneously once-weekly.

DRUG

Semaglutide

Semaglutide will be administered subcutaneously once-weekly.

DRUG

Semaglutide Placebo

Semaglutide placebo will be administered subcutaneously once-weekly.

Sponsors & Collaborators

Principal Investigators

  • Clinical Transparency dept. 2834 · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2027-10-04
Completion
2027-11-15
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Hungary
  • Poland
  • Romania
  • Slovakia
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07668388 on ClinicalTrials.gov